Reduce reproductive healthcare costs

To keep reproductive health care services and medications affordable, Alliance Governors have shared practical strategies to increase Medicaid reimbursement rates, bundle billing codes, and enact other novel affordability and workforce expansion measures.
Trump’s IVF Executive Order Is a Distraction
  • Glamour
  • Alliance
    •
  • Glamour
  • Alliance
    •  February 20, 2025 • Stephanie McNeal

    Trump’s IVF Executive Order Is a Distraction

    Stephanie McNeal

    “True reproductive freedom means not just protecting access to IVF but ensuring that every individual has the ability to make decisions about their bodies, their health, and their families—no matter where they live, who they are, or their economic background,” Christina Chang, Executive Director of the Reproductive Freedom Alliance, says.
    Governor Kotek’s 2025 Budget Proposal Prioritizes Reproductive Health Equity
  • Oregon
    •
  • Oregon
    •

    Governor Kotek’s 2025 Budget Proposal Prioritizes Reproductive Health Equity

    These investments include a $2.5 million funding allocation to support grants aimed at expanding reproductive health equity, which will cover patient navigation services and help providers upgrade facilities to meet the growing demand for care following the Dobbs decision. Additionally, another $2.5 million will be set aside in a reserve to safeguard Oregon against potential disruptions in care if federal reproductive health program funding decreases under a new administration.
    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine
  • Oregon
    •
  • Oregon
    •

    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine

    Governor Kotek and 21 other governors filed an amicus brief with the U.S. Supreme Court in support of abortion rights in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine. In this brief, the Reproductive Freedom Alliance governors argued that if the Court reverses FDA approval of Mifepristone and limits access to the vital medicine, it could undermine Governors’ ability to provide adequate healthcare services and would have far-reaching implications beyond reproductive healthcare.
    Lawsuit Over Unnecessary Abortion Medication Restrictions
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Lawsuit Over Unnecessary Abortion Medication Restrictions

    As the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration lawsuit was underway, Oregon’s Attorney General Ellen Rosenblum joined Washington State’s Attorney General Bob Ferguson in co-leading a multi-state lawsuit against the FDA to protect enhanced access to mifepristone. The outcome of this lawsuit was Judge Thomas Rice’s decision barring the FDA from making any changes that could reduce the availability of mifepristone in the 17 states that signed on to the lawsuit.
    Mifepristone Stockpile
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Mifepristone Stockpile

    In response to the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration’s lawsuit challenging the FDA’s approval of the medication abortion drug mifepristone, Oregon secured a three-year supply of the drug. This stockpile ensures that patients seeking abortion services in Oregon will continue to have access to a safe and effective method of abortion. Oregon also developed a plan to distribute its supply of mifepristone equitably to eligible prescribers.
    Reproductive Health Policy Workgroup
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Reproductive Health Policy Workgroup

    The Oregon Health Authority (OHA) established a Reproductive Health Policy Workgroup to provide a coordinated, equity-centered, and comprehensive approach to advancing reproductive health goals in Oregon. Composed of representatives from a diverse set of programs and divisions within the agency, as well as agencies whose work impacts reproductive health, the workgroup provided input and coordinated on efforts related to reproductive health and autonomy from a holistic and intersectional perspective.
    Oregon Health Authority’s Reproductive Health Program
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Oregon Health Authority’s Reproductive Health Program

    The Oregon Health Authority’s Reproductive Health Program has leveraged diverse funding streams to create more efficient and flexible funding sources for Oregon’s network of publicly funded reproductive health clinics, including new infrastructure grants using Title X funds to bolster access to reproductive health services.
    Reproductive Health Infrastructure Investments
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Reproductive Health Infrastructure Investments

    Oregon allocated $3.4 million dollars to the Oregon Health Authority (OHA) as part of Public Health Modernization to support reproductive health infrastructure development. This funding created a state-wide abortion access website, provided OHA-wide reproductive health services reimbursement rate revisions and alignment, and provided infrastructure grants to service providers across the state.
    The Reproductive Health and Access to Care Act
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    The Reproductive Health and Access to Care Act

    This comprehensive public law expands access to reproductive health and gender-affirming care and establishes protections for those seeking and those providing this care by codifying abortion rights, protecting providers and patients, and expanding access to reproductive health care.
    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine
  • New York
    •
  • New York
    •  July 22, 2024

    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine

    Governor Hochul and 21 other governors filed an amicus brief with the U.S. Supreme Court in support of abortion rights in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine. In this brief, the Reproductive Freedom Alliance governors argued that if the Court reverses FDA approval of Mifepristone and limits access to the vital medicine, it could undermine Governors’ ability to provide adequate healthcare services and would have far-reaching implications beyond reproductive healthcare.